CoChat
Sign Up
Cited by 261Cancer Cells and MetastasisCell Adhesion Molecules ResearchMechanisms of cancer metastasis

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer

Open access
Taftaf, Rokana, Liu, Xia, Singh, Salendra, Jia, Yuzhi, Dashzeveg, Nurmaa K., Hoffmann, Andrew D., El-Shennawy, Lamiaa, Ramos, Erika K., Adorno-Cruz, Valery, Schuster, Emma J., Scholten, David, Patel, Dhwani, Zhang, Youbin, Davis, Andrew A., Reduzzi, Carolina, Cao, Yue, D’Amico, Paolo, Shen, Yang, Cristofanilli, Massimo, Muller, William A., Varadan, Vinay, Liu, Huiping·2021·Nature Communications
DOI 10.1038/s41467-021-25189-zPMC PMC8358026
Open this paper in CoChat — free accountOpen PDF

Abstract

Circulating tumor cell (CTC) clusters mediate metastasis at a higher efficiency and are associated with lower overall survival in breast cancer compared to single cells. Combining single-cell RNA sequencing and protein analyses, here we report the profiles of primary tumor cells and lung metastases of triple-negative breast cancer (TNBC). ICAM1 expression increases by 200-fold in the lung metastases of three TNBC patient-derived xenografts (PDXs). Depletion of ICAM1 abrogates lung colonization of TNBC cells by inhibiting homotypic tumor cell-tumor cell cluster formation. Machine learning-based algorithms and mutagenesis analyses identify ICAM1 regions responsible for homophilic ICAM1-ICAM1 interactions, thereby directing homotypic tumor cell clustering, as well as heterotypic tumor-endothelial adhesion for trans-endothelial migration. Moreover, ICAM1 promotes metastasis by activating cellular pathways related to cell cycle and stemness. Finally, blocking ICAM1 interactions significantly inhibits CTC cluster formation, tumor cell transendothelial migration, and lung metastasis. Therefore, ICAM1 can serve as a novel therapeutic target for metastasis initiation of TNBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-25189-z

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Single-cell RNA sequencing profiles comparing breast cancer cells from primary and metastatic tumor sites. a A schematic showing the single-cell RNA sequencing of the sorted cells from L2T- or L2G-labeled TNBC PDX (mice 1 and 2) or MDA-MB-231 tumor (mouse 3)-bearing mice, both primary breast tumors and lung metastases (early micrometastases). b Heatmap denoting expression magnitude estimates in log scale (red color) for ICAM1 and co-expressed stemness signature genes in primary tumor cells and lung metastases (N = 3 mice, 2 with TN PDXs and 1 with MDA-MB-231 tumor). Genes are sorted according to their correlation with ICAM1 across all cells, as denoted by the gray bars on the right (top highest to bottom lowest). The bottom list of CD44, GAPDH, ACTB, eGFP, and tdTomato serve as control genes without significant changes between primary tumor cells and lung metastases. c Representative ICAM1 expression in L2T+ or L2G+ primary tumor cells and lung metastases determined by flow cytometry from different breast cancer PDX models (TN1, TN2, and TN3). Flow profile gates are shown in Supplementary Fig. 1d. d Quantitative data of the differential ICAM1 expression in PDX primary tumors versus lung metastasis from c. n = 3 biological replicates (mice) for each model. One-sided t test *P = 0.04; **P = 0.01; *P = 0.02. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). e Representative IHC staining images of ICAM1 expression (brown color) in primary tumors and lung metastases from PDX TN1 and TN2 models validating c and d. f Distribution of ICAM1 expression across PAM50 subtypes in the TCGA BRCA cohort (N = 1037). Basal-like and HER2-enriched subtypes are the top two exhibiting significantly higher ICAM1 expression as compared to normal breast tissue (percentage of cases above the blue line value are shown for each subtype). Statistical significance was assessed using a two-sided Student’s t test. *P < 0.05, **P < 0.01, and ****P ≤ 0.0001. g Schematic and flow histogram analyses of the orthotopically implanted TN1-PDX tumors with or without ICAM1 overexpression (OE) at the 4th mammary fat pads. h. PDX TN1 tumor weights 2 months after orthotopic injections of TN1 cells with ICAM1 OE and control vector (Con) (2.5e5 cells into one mammary fat pad/mouse). n = 3 mice per cell group. Two-sided t test *P = 0.04. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). i, j Representative lung images and normalized BLI signals (total flux) of spontaneous lung metastases in orthotopically implanted ICAM1 OE and control TN1 tumor-bearing mice as in g, h. n = 3 mice per group. Two-sided t test **P = 0.003. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). k Schematic and flow histogram analyses of tail vein injected MDA-MB-231 tumor cells transfectd with siRNA control (siCon) and siICAM1. l, m. Representative images and quantitative data of BLI signal of mice injected with siCon and siICAM1-transfected MDA-MB-231 cells via tail vein (n = 4 mice per cell group. Two-sided t test **P = 0.01 for time point comparisons. N = 6 independent experiments). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum).
Fig. 1 Single-cell RNA sequencing profiles comparing breast cancer cells from primary and metastatic tumor sites. a A schematic showing the single-cell RNA sequencing of the sorted cells from L2T- or L2G-labeled TNBC PDX (mice 1 and 2) or MDA-MB-231 tumor (mouse 3)-bearing mice, both primary breast tumors and lung metastases (early micrometastases). b Heatmap denoting expression magnitude estimates in log scale (red color) for ICAM1 and co-expressed stemness signature genes in primary tumor cells and lung metastases (N = 3 mice, 2 with TN PDXs and 1 with MDA-MB-231 tumor). Genes are sorted according to their correlation with ICAM1 across all cells, as denoted by the gray bars on the right (top highest to bottom lowest). The bottom list of CD44, GAPDH, ACTB, eGFP, and tdTomato serve as control genes without significant changes between primary tumor cells and lung metastases. c Representative ICAM1 expression in L2T+ or L2G+ primary tumor cells and lung metastases determined by flow cytometry from different breast cancer PDX models (TN1, TN2, and TN3). Flow profile gates are shown in Supplementary Fig. 1d. d Quantitative data of the differential ICAM1 expression in PDX primary tumors versus lung metastasis from c. n = 3 biological replicates (mice) for each model. One-sided t test *P = 0.04; **P = 0.01; *P = 0.02. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). e Representative IHC staining images of ICAM1 expression (brown color) in primary tumors and lung metastases from PDX TN1 and TN2 models validating c and d. f Distribution of ICAM1 expression across PAM50 subtypes in the TCGA BRCA cohort (N = 1037). Basal-like and HER2-enriched subtypes are the top two exhibiting significantly higher ICAM1 expression as compared to normal breast tissue (percentage of cases above the blue line value are shown for each subtype). Statistical significance was assessed using a two-sided Student’s t test. *P < 0.05, **P < 0.01, and ****P ≤ 0.0001. g Schematic and flow histogram analyses of the orthotopically implanted TN1-PDX tumors with or without ICAM1 overexpression (OE) at the 4th mammary fat pads. h. PDX TN1 tumor weights 2 months after orthotopic injections of TN1 cells with ICAM1 OE and control vector (Con) (2.5e5 cells into one mammary fat pad/mouse). n = 3 mice per cell group. Two-sided t test *P = 0.04. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). i, j Representative lung images and normalized BLI signals (total flux) of spontaneous lung metastases in orthotopically implanted ICAM1 OE and control TN1 tumor-bearing mice as in g, h. n = 3 mice per group. Two-sided t test **P = 0.003. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). k Schematic and flow histogram analyses of tail vein injected MDA-MB-231 tumor cells transfectd with siRNA control (siCon) and siICAM1. l, m. Representative images and quantitative data of BLI signal of mice injected with siCon and siICAM1-transfected MDA-MB-231 cells via tail vein (n = 4 mice per cell group. Two-sided t test **P = 0.01 for time point comparisons. N = 6 independent experiments). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum).CC BY · PubMed Central
Fig. 2 ICAM1 mediates tumor cell clustering through homophilic interaction. a Representative IHC staining images of ICAM1− single CTC and ICAM1+ CTC cluster (5-cell) (brown) in the lung vasculature of the PDX TN1-bearing mouse. Minimal 3 sets of independent images have shown similar patterns. b Representative images of CellSearch-analyzed CTCs in breast cancer (BC) patients: CD45−, cytokeratin (CK)+ (green), DAPI+ (purple), ICAM1− or ICAM1+ (gray) (two single cells and a three-cell cluster). c Bar graph of the proportion of flow analyzed CD45−ICAM1+ single (blue) and clustered (orange) CTCs in each of 51 stage III–IV BC patients (N = 51 patients. Two-sided t test ****P = 0.00007). d, e Representative images (d) and quantitative cluster counts (e) of ICAM1+ and ICAM1− cells sorted from PDX TN1 OE models showing different cluster formation efficiencies ex vivo (n = 10 biological replicates. Data are presented as mean values ± SEM. Error bars represent SE values. Two-sided t test *P < 0.02. N = 2 independent experiments). f, g Representative images (f) and quantified cluster sizes (g) of MDA-MB-231 cells transfected with siRNA control (Con) and siICAM1, and resuspended in poly-HEMA treated plates for cluster formation (n = 10 biological replicates. Data are presented as mean values ± SD. Error bars represent SD values. Two-sided t test ***P = 0.0003. N = 4 independent experiments). h, i Diagram of solid phase self-interaction assay (h) and quantified binding (i) of biotin-conjugated ICAM1 and BSA at 1 μg to the solid phase coated with ICAM1 (1 µg), measured as OD450 units (two-sided t test ****P = 0.0000003. N = 2 independent experiments). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). j Co-IP detection of ICAM1-Flag and ICAM-Myc intercellular homodimers. Upper panel, diagram of two HEK-293T cells transfected with C-terminal Flag-tagged and Myc-tagged ICAM1, respectively. Lower panel, immunoblots for Flag, Myc, and ICAM1, respectively, following co-IP with anti-Flag antibody. N = 3 independent experiments. k ICAM1 extracellular homodimer structure model with interacting domains between II-IV, III-III, and IV-II of two molecules extended from opposite directions. l Co-IP detection of ICAM1-Flag with ICAM-Myc variants transfected in two sets of HEK293T cells separately. Upper panel, diagram of two HEK-293T cells transfected with ICAM1-Flag (WT) and ICAM1-Myc variants (1 of 5 different variants). Lower panel, immunoblots for Flag and Myc, following co-IP with anti-Flag showing lost interactions with mutant ICAM1. Colored asterisks indicate the various WT and variant constructs (N = 2 independent experiments).
Fig. 2 ICAM1 mediates tumor cell clustering through homophilic interaction. a Representative IHC staining images of ICAM1− single CTC and ICAM1+ CTC cluster (5-cell) (brown) in the lung vasculature of the PDX TN1-bearing mouse. Minimal 3 sets of independent images have shown similar patterns. b Representative images of CellSearch-analyzed CTCs in breast cancer (BC) patients: CD45−, cytokeratin (CK)+ (green), DAPI+ (purple), ICAM1− or ICAM1+ (gray) (two single cells and a three-cell cluster). c Bar graph of the proportion of flow analyzed CD45−ICAM1+ single (blue) and clustered (orange) CTCs in each of 51 stage III–IV BC patients (N = 51 patients. Two-sided t test ****P = 0.00007). d, e Representative images (d) and quantitative cluster counts (e) of ICAM1+ and ICAM1− cells sorted from PDX TN1 OE models showing different cluster formation efficiencies ex vivo (n = 10 biological replicates. Data are presented as mean values ± SEM. Error bars represent SE values. Two-sided t test *P < 0.02. N = 2 independent experiments). f, g Representative images (f) and quantified cluster sizes (g) of MDA-MB-231 cells transfected with siRNA control (Con) and siICAM1, and resuspended in poly-HEMA treated plates for cluster formation (n = 10 biological replicates. Data are presented as mean values ± SD. Error bars represent SD values. Two-sided t test ***P = 0.0003. N = 4 independent experiments). h, i Diagram of solid phase self-interaction assay (h) and quantified binding (i) of biotin-conjugated ICAM1 and BSA at 1 μg to the solid phase coated with ICAM1 (1 µg), measured as OD450 units (two-sided t test ****P = 0.0000003. N = 2 independent experiments). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). j Co-IP detection of ICAM1-Flag and ICAM-Myc intercellular homodimers. Upper panel, diagram of two HEK-293T cells transfected with C-terminal Flag-tagged and Myc-tagged ICAM1, respectively. Lower panel, immunoblots for Flag, Myc, and ICAM1, respectively, following co-IP with anti-Flag antibody. N = 3 independent experiments. k ICAM1 extracellular homodimer structure model with interacting domains between II-IV, III-III, and IV-II of two molecules extended from opposite directions. l Co-IP detection of ICAM1-Flag with ICAM-Myc variants transfected in two sets of HEK293T cells separately. Upper panel, diagram of two HEK-293T cells transfected with ICAM1-Flag (WT) and ICAM1-Myc variants (1 of 5 different variants). Lower panel, immunoblots for Flag and Myc, following co-IP with anti-Flag showing lost interactions with mutant ICAM1. Colored asterisks indicate the various WT and variant constructs (N = 2 independent experiments).CC BY · PubMed Central
Fig. 3 Downstream targets of ICAM1 in regulating metastasis. a Down-regulated pathways upon ICAM1 knockdown in MDA-MB-231 cells, analyzed by RNA sequencing (top) and mass spectrometry analysis (bottom). b GSEA of the gene sets for histone deacetylase targets, H3K27ME3, and EZH2 targets enriched among the up-regulated genes in MDA-MB-231 ICAM1 knockdown cells in comparison to siRNA control, identified by RNA sequencing. c Immunoblots of ICAM1 and CDK6 in MDA-MB-231 cells transfected with control siRNAs (siCon) and siICAM1 for gene knockdown. N = 3 independent experiments. d, e Representative images (d) and mammosphere quantitation (e) of MDA-MB-231 cells transfected with siCon, siICAM1, and siCDK6 (n = 3 biological replicates, two-sided t test **P = 0.006; ***P = 0.0008. N = 3 independent experiments. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). f–h Representative images (f) and quantitative data (g, h) of BLI signals of mice injectd with siCon, siICAM1, and siCDK6-transfected MDA-MB-231 cells via tail vein (n = 3 mice per cell group. g Data are presented as mean values ± SD, two-sided t test *P < 0.05; **P ≤ 0.01. N = 4 independent experiments. h The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). i, j Representative images (i) and counts (j) of proliferative MDA-MB-231 (50k cells/well) transfected with siCon, siICAM1, and siCDK6. Cell numbers were measured via hemocytometer counting 48 h after seeding (n = 4 biological replicates. two-sided t test *P = 0.04; **P = 0.01. N = 3 independent experiments. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). k Pearson’s pairwise correlation plot of ICAM1 versus CDK6 expression in breast cancer patients (n = 4712), by BC Gene-Expression Miner v4.4. ICAM1 vs. CDK6 R = 0.40. ****P < 0.0001.
Fig. 3 Downstream targets of ICAM1 in regulating metastasis. a Down-regulated pathways upon ICAM1 knockdown in MDA-MB-231 cells, analyzed by RNA sequencing (top) and mass spectrometry analysis (bottom). b GSEA of the gene sets for histone deacetylase targets, H3K27ME3, and EZH2 targets enriched among the up-regulated genes in MDA-MB-231 ICAM1 knockdown cells in comparison to siRNA control, identified by RNA sequencing. c Immunoblots of ICAM1 and CDK6 in MDA-MB-231 cells transfected with control siRNAs (siCon) and siICAM1 for gene knockdown. N = 3 independent experiments. d, e Representative images (d) and mammosphere quantitation (e) of MDA-MB-231 cells transfected with siCon, siICAM1, and siCDK6 (n = 3 biological replicates, two-sided t test **P = 0.006; ***P = 0.0008. N = 3 independent experiments. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). f–h Representative images (f) and quantitative data (g, h) of BLI signals of mice injectd with siCon, siICAM1, and siCDK6-transfected MDA-MB-231 cells via tail vein (n = 3 mice per cell group. g Data are presented as mean values ± SD, two-sided t test *P < 0.05; **P ≤ 0.01. N = 4 independent experiments. h The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). i, j Representative images (i) and counts (j) of proliferative MDA-MB-231 (50k cells/well) transfected with siCon, siICAM1, and siCDK6. Cell numbers were measured via hemocytometer counting 48 h after seeding (n = 4 biological replicates. two-sided t test *P = 0.04; **P = 0.01. N = 3 independent experiments. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). k Pearson’s pairwise correlation plot of ICAM1 versus CDK6 expression in breast cancer patients (n = 4712), by BC Gene-Expression Miner v4.4. ICAM1 vs. CDK6 R = 0.40. ****P < 0.0001.CC BY · PubMed Central
Fig. 4 ICAM1 mediates transendothelial migration of breast cancer cells. a Diagram of TEM assay with HUVEC cell-coated transwell inserts and tumor cells seeded on the top. Tumor cells transmigrated to the bottom were measured 24 h after seeding. (MDA-MB-231 tumor cells; green, HUVEC; purple, and ICAM1 protein; blue). b Representative images (top) and quantitative analyses (bottom) of TNBC cells transmigrated to the bottom chamber, including four conditions (from left to right): (1) siRNA control tumor cells and HUVECs; (2) ICAM1 knockdown in endothelial cells (EC); (3) ICAM1 knockdown in tumor cells; (4) ICAM1 knockdown in both tumor cells and HUVECs (n = 3 biological replicates. Two-sided t test *P = 0.04; **P = 0.007; ***P = 0.0006. NS not significant. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). c, d Time-lapse co-culture images at 0 and 24 h of incubation with TNBC cells (green) and endothelial cells (red) (c) and quantitative analyses of aggregates (d) following ICAM1 knockdown in both cell types (n = 8 biological replicates. Data are presented as mean values ± SD. Error bars represent SD values. Two-sided t test ****P = 0.0000005). e, f Representative images (e) and quantitative analyses (f) of TNBC cell cluster formation in the presence of IgG control or anti-ICAM1 neutralizing antibody (n = 10 biological replicates, Data are presented as mean values ± SEM. Error bars represent SE values. Two-sided t test **P = 0.005). g, h Diagram and representative images of TEM assay (g) and quantitative analysis (h) of breast tumor cells transmigrated to the bottom chamber in the presence of IgG control or anti-ICAM1 neutralizing antibody (n = 3 biological replicates. Two-sided t test **P = 0.002). (Diagram: MDA-MB-231 tumor cells; green, HUVEC; purple, ICAM1 protein; blue, and anti-ICAM1 antibody; yellow). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum).
Fig. 4 ICAM1 mediates transendothelial migration of breast cancer cells. a Diagram of TEM assay with HUVEC cell-coated transwell inserts and tumor cells seeded on the top. Tumor cells transmigrated to the bottom were measured 24 h after seeding. (MDA-MB-231 tumor cells; green, HUVEC; purple, and ICAM1 protein; blue). b Representative images (top) and quantitative analyses (bottom) of TNBC cells transmigrated to the bottom chamber, including four conditions (from left to right): (1) siRNA control tumor cells and HUVECs; (2) ICAM1 knockdown in endothelial cells (EC); (3) ICAM1 knockdown in tumor cells; (4) ICAM1 knockdown in both tumor cells and HUVECs (n = 3 biological replicates. Two-sided t test *P = 0.04; **P = 0.007; ***P = 0.0006. NS not significant. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). c, d Time-lapse co-culture images at 0 and 24 h of incubation with TNBC cells (green) and endothelial cells (red) (c) and quantitative analyses of aggregates (d) following ICAM1 knockdown in both cell types (n = 8 biological replicates. Data are presented as mean values ± SD. Error bars represent SD values. Two-sided t test ****P = 0.0000005). e, f Representative images (e) and quantitative analyses (f) of TNBC cell cluster formation in the presence of IgG control or anti-ICAM1 neutralizing antibody (n = 10 biological replicates, Data are presented as mean values ± SEM. Error bars represent SE values. Two-sided t test **P = 0.005). g, h Diagram and representative images of TEM assay (g) and quantitative analysis (h) of breast tumor cells transmigrated to the bottom chamber in the presence of IgG control or anti-ICAM1 neutralizing antibody (n = 3 biological replicates. Two-sided t test **P = 0.002). (Diagram: MDA-MB-231 tumor cells; green, HUVEC; purple, ICAM1 protein; blue, and anti-ICAM1 antibody; yellow). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum).CC BY · PubMed Central
Fig. 5 ICAM1 is a therapeutic target of TNBC metastasis. a Differences in distant metastasis-free survival (DMFS) of patients with breast tumors exhibiting high versus low ICAM1 expression in the GSE25055 (N = 306) cohort. Note that patients with tumors expressing higher than median ICAM1 expression (red) are associated with significantly poorer DMFS (Logrank P = 0.035). b Differences in disease-specific survival (DSS) of patients with breast tumors exhibiting high versus low ICAM1 expression alone (left panel) or in combination with a 98-gene Stemness Signature Index (right panel) in the GSE1456-GPL96 (N = 159) cohort. Note that patients with tumors harboring higher than median ICAM1 expression (left panel, red) exhibit significantly poorer DSS (Logrank P = 0.025). Similarly, breast cancers expressing higher than median Stemness Signature Index in addition to higher than median ICAM1 expression (Dual-High, red) exhibit poorer DSS (Logrank P = 0.034). c, d Representative images (c) and quantitative data (d) of BLI signals in mice on Day 0 (D0, 0 h) and Day 1 (D1, 24 h, dissected lungs) after injection of sorted ICAM1+ and ICAM1− TN1 PDX cells via tail vein (n = 4 mice per cell group. Two-sided t test **P = 0.005). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). e–g Representative BLI images of mice at 0 h and dissected lungs at 10 h after tumor cell injections via tail vein (e), normalized metastatic seeding to the lungs (f), and L2G+ CTC analysis (%) in the blood (g). The mice were pretreated with IgG or anti-ICAM1 neutralizing antibody (80 µg/mouse) via tail vein, and 3 h later followed by a tail vein injection of MDA-MB-231 cells (1 × 105 cells) and the antibody (100 μg, pre-incubated with cells for 30 min). Lungs were collected 10 h after injection. (n = 3 mice per group. Two-sided t test **P = 0.008; **P = 0.01. N = 2 independent experiments. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). h, i Representative BLI images of mice on day 0 post orthotopic implantations of MDA-MB-231 tumor cells, pictures of dissected breast tumors, and BLI of dissected lungs (h) and quantitative lung metastasis after normalization by tumor weight of each mouse (i). The mice were given long-term treatment with IgG or anti-ICAM1 antibody (100 µg/mouse, twice a week for 4 weeks) (n = 3 mice per group. Two-sided t test **P = 0.01). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). j Diagram of ICAM1+ tumor cells initiating multicellular cluster formation in the circulation, directing TEM, and mediating lung metastasis; partially through sustained expression of CDK6. Blocking the ICAM1 intercellular homophilic interactions between tumor-tumor and tumor-endothelial cells with neutralizing antibodies (gold) will inhibit CTC cluster formation and TEM, and eventually decrease or block metastasis. (ICAM1+ tumor cells; green, ICAM1 protein; blue, ICAM1− tumor cells; beige, Endothelial cells; purple, and anti-ICAM1 antibody; yellow).
Fig. 5 ICAM1 is a therapeutic target of TNBC metastasis. a Differences in distant metastasis-free survival (DMFS) of patients with breast tumors exhibiting high versus low ICAM1 expression in the GSE25055 (N = 306) cohort. Note that patients with tumors expressing higher than median ICAM1 expression (red) are associated with significantly poorer DMFS (Logrank P = 0.035). b Differences in disease-specific survival (DSS) of patients with breast tumors exhibiting high versus low ICAM1 expression alone (left panel) or in combination with a 98-gene Stemness Signature Index (right panel) in the GSE1456-GPL96 (N = 159) cohort. Note that patients with tumors harboring higher than median ICAM1 expression (left panel, red) exhibit significantly poorer DSS (Logrank P = 0.025). Similarly, breast cancers expressing higher than median Stemness Signature Index in addition to higher than median ICAM1 expression (Dual-High, red) exhibit poorer DSS (Logrank P = 0.034). c, d Representative images (c) and quantitative data (d) of BLI signals in mice on Day 0 (D0, 0 h) and Day 1 (D1, 24 h, dissected lungs) after injection of sorted ICAM1+ and ICAM1− TN1 PDX cells via tail vein (n = 4 mice per cell group. Two-sided t test **P = 0.005). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). e–g Representative BLI images of mice at 0 h and dissected lungs at 10 h after tumor cell injections via tail vein (e), normalized metastatic seeding to the lungs (f), and L2G+ CTC analysis (%) in the blood (g). The mice were pretreated with IgG or anti-ICAM1 neutralizing antibody (80 µg/mouse) via tail vein, and 3 h later followed by a tail vein injection of MDA-MB-231 cells (1 × 105 cells) and the antibody (100 μg, pre-incubated with cells for 30 min). Lungs were collected 10 h after injection. (n = 3 mice per group. Two-sided t test **P = 0.008; **P = 0.01. N = 2 independent experiments. The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). h, i Representative BLI images of mice on day 0 post orthotopic implantations of MDA-MB-231 tumor cells, pictures of dissected breast tumors, and BLI of dissected lungs (h) and quantitative lung metastasis after normalization by tumor weight of each mouse (i). The mice were given long-term treatment with IgG or anti-ICAM1 antibody (100 µg/mouse, twice a week for 4 weeks) (n = 3 mice per group. Two-sided t test **P = 0.01). The boxes range from the first to third quartile with x in a box indicating mean value and whisker lines extending to outliers (minimum and maximum). j Diagram of ICAM1+ tumor cells initiating multicellular cluster formation in the circulation, directing TEM, and mediating lung metastasis; partially through sustained expression of CDK6. Blocking the ICAM1 intercellular homophilic interactions between tumor-tumor and tumor-endothelial cells with neutralizing antibodies (gold) will inhibit CTC cluster formation and TEM, and eventually decrease or block metastasis. (ICAM1+ tumor cells; green, ICAM1 protein; blue, ICAM1− tumor cells; beige, Endothelial cells; purple, and anti-ICAM1 antibody; yellow).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

Sorted by citations

Items 101–200 of 261

Related

See all

Metadata

Authors
Taftaf, R., Liu, X., Singh, S., Jia, Y., Dashzeveg, N. K., Hoffmann, A. D., El-Shennawy, L., Ramos, E. K., Adorno-Cruz, V., Schuster, E. J., Scholten, D., Patel, D., Zhang, Y., Davis, A. A., Reduzzi, C., Cao, Y., D’Amico, P., Shen, Y., Cristofanilli, M., Muller, W. A., Varadan, V., & Liu, H.
Affiliations
  • Northwestern University (US)
  • Case Comprehensive Cancer Center (US)
  • Texas A&M University System (US)
Corresponding author
Liu, Huiping
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2021-08-11
Volume
12
Issue
1
Pages
4867-4867
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-021-25189-z
PMC
PMC8358026
OpenAlex
W3189505974
Cited by
261
References
75
Citations by year
2026: 42 · 2025: 54 · 2024: 57 · 2023: 67 · 2022: 38 · 2021: 3
FWCI
15.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Health & Human Services | National Institutes of Health (CA080621-15, R35GM124952)
  • Susan G. Komen (CCR18548501)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA245699)
  • U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R00CA160638)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
ICAM-1, circulating tumor cell clusters, triple-negative breast cancer, lung metastasis, transendothelial migration, homotypic cell adhesion, metastasis initiation, therapeutic target, cell cycle, stemness, patient-derived xenografts
MeSH terms
Animals, Cell Aggregation, Cell Cycle, Cell Transformation, Neoplastic, Humans, Lung Neoplasms, Neoplastic Cells, Circulating, Biomarkers, Tumor, Signal Transduction, Intercellular Adhesion Molecule-1, Mice, Protein Interaction Domains and Motifs, Transendothelial and Transepithelial Migration, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review